ITOPRIDE PRESCRIBING INFORMATION PDF

View All Methocarbamol Description Methocarbamol tablet, USP, a carbamate derivative of guaifenesin, is a central nervous system CNS depressant with sedative and musculoskeletal relaxant properties. Its molecular weight is The structural formula is shown below. Methocarbamol is a white powder, sparingly soluble in water and in chloroform, soluble in alcohol only with heating , insoluble in benzene and in n-hexane. Methocarbamol tablets, USP are available as mg and mg tablets for oral administration.

Author:Meztizuru Mozragore
Country:Antigua & Barbuda
Language:English (Spanish)
Genre:Sex
Published (Last):5 October 2012
Pages:206
PDF File Size:9.68 Mb
ePub File Size:3.1 Mb
ISBN:633-5-29214-382-7
Downloads:72341
Price:Free* [*Free Regsitration Required]
Uploader:Kajit



View All Methocarbamol Description Methocarbamol tablet, USP, a carbamate derivative of guaifenesin, is a central nervous system CNS depressant with sedative and musculoskeletal relaxant properties. Its molecular weight is The structural formula is shown below. Methocarbamol is a white powder, sparingly soluble in water and in chloroform, soluble in alcohol only with heating , insoluble in benzene and in n-hexane.

Methocarbamol tablets, USP are available as mg and mg tablets for oral administration. Methocarbamol tablets, USP mg are light orange colored, round shaped film coated tablets debossed with "G" above the score line on one side and "" on other side.

Methocarbamol tablets, USP mg are light orange colored, caplet shaped film coated tablets debossed with "G" on one side and "" on other side.

Methocarbamol tablets, USP mg and mg contain the following inactive ingredients: colloidal silicon dioxide, maize starch, povidone, sodium lauryl sulfate, sodium starch glycolate, and stearic acid.

Methocarbamol - Clinical Pharmacology The mechanism of action of Methocarbamol in humans has not been established, but may be due to general central nervous system CNS depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber. Pharmacokinetics In healthy volunteers, the plasma clearance of Methocarbamol ranges between 0.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of Methocarbamol also is likely. Essentially all Methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged Methocarbamol also are excreted in the urine. The mode of action of Methocarbamol has not been clearly identified, but may be related to its sedative properties.

Methocarbamol does not directly relax tense skeletal muscles in man. Contraindications Methocarbamol tablets are contraindicated in patients hypersensitive to Methocarbamol or to any of the tablet components. Warnings Since Methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of Methocarbamol tablets has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to Methocarbamol. Therefore, Methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards see PRECAUTIONS , Pregnancy.

Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that Methocarbamol therapy does not adversely affect their ability to engage in such activities. Precautions Information for Patients Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.

Because Methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants. Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, Methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies to evaluate the carcinogenic potential of Methocarbamol have not been performed.

No studies have been conducted to assess the effect of Methocarbamol on mutagenesis or its potential to impair fertility. It is also not known whether Methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol tablets should be given to a pregnant woman only if clearly needed.

Safe use of Methocarbamol tablet has not been established with regard to possible adverse effects upon fetal development. Therefore, Methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards see WARNINGS.

Because many drugs are excreted in human milk, caution should be exercised when Methocarbamol tablets are administered to a nursing woman. Pediatric Use Safety and effectiveness of Methocarbamol tablets in pediatric patients below the age of 16 have not been established. Overdose of Methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.

In post-marketing experience, deaths have been reported with an overdose of Methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs. Treatment Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary.

The usefulness of hemodialysis in managing overdose is unknown. For severe conditions 8 grams a day may be administered. Thereafter, the dosage can usually be reduced to approximately 4 grams a day. How is Methocarbamol Supplied Methocarbamol tablets, USP mg are light orange colored, round shaped film coated tablets debossed with "G" above the score line on one side and "" on other side.

Dispense in tight container.

ALPINE W205 MANUAL PDF

ITOPRIDE PRESCRIBING INFORMATION PDF

The dose is usually taken on an empty stomach about an hour before meals. Itopride was shown to significantly improve symptoms in patients with functional dyspepsia and motility disorders in placebo-controlled trials. These studies concluded that the reduction in the severity of symptoms of functional dyspepsia after 8 weeks of treatment with itopride indicated that itopride was significantly superior to placebo and that itopride yielded a greater rate of response than placebo in significantly reducing pain and fullness. However, this does not necessarily indicate that itopride is not effective or safe. Patients taking itopride should report any side-effects to their treating physician. Itopride is contraindicated in hypersensitivity to itopride or benzamides ; lactation , GI hemorrhage , obstruction or perforation.

EL NINO SIN NOMBRE DAVID PELZER PDF

Mesalamine

Telmaran Data on long-term use are not available. Itopride information from DrugsUpdate Itopride activates acetylcholine release and inhibits degradation. Itopride and Geriatic Information Not Available. Presdribing listed are the International and Indian trade name s of the drug and its price list.

Related Articles